Roar Bidco News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Roar BidCo's outstanding public offer for Recipharm AB (publ) - Consent granted to correct error in the Convertible Bond Terms On 14 December 2020, EQT IX 1 2 ("Roar BidCo"), announced a public offer to the shareholders and holders of the Senior Unsecured Convertible Bonds (the "Convertible Bonds") ("Holders of Convertible Bonds") in Recipharm AB (publ) ("Recipharm" or the "Company") to tender all their shares 3 and Convertible Bonds to Roar BidCo (the "Offer"). An offer document relating to the Offer was made public on 17 December 2020 (the "Offer Document"). The Offer was subsequently incr...

Electrolux Nomination Committee's proposal for election of board members STOCKHOLM, Feb. 1, 2021 /PRNewswire/ — In preparation for the Electrolux Annual General Meeting on March 25, Electrolux Nomination Committee has decided to propose the re-election of all board members except Kai Wärn, who has declined re-election. Staffan Bohman is proposed to be re-elected as Chairman of the Board of Directors, and Petra Hedengran, Henrik Henriksson, Ulla Litzén, Karin Overbeck, Fredrik Person, David Porter and Jonas Samuelson as Board Members. The Nomination Committee comprises Johan Forssell (...

Offer document regarding Roar BidCo AB's cash offer to the shareholders and Holders of Convertible Bonds in Recipharm AB (publ) made public: EQT Tel: + 46 8 506 55 334, email: press@eqtpartners.com For administrative questions regarding the Offer, please contact your bank or the nominee registered as holder of your shares, or, in respect of the Convertible Bonds, Lucid Issuer Services Limited: Lucid Issuer Services Limited Attention: Owen Morris Email: recipharm@lucid-is.com The information in this press release was submitted for publication by Roar BidCo (contact details to EQT Press Office ...

By Reuters Staff 2 Min Read STOCKHOLM (Reuters) -Buyout group EQT on Monday announced a cash offer for Swedish contract pharmaceutical maker Recipharm, valuing the company at 23.6 billion Swedish crowns ($2.80 billion). Recipharm, a contract development and manufacturing organisation (CDMO) for the pharma industry, recently signed a preliminary deal with Moderna Inc to fill and seal the packaging for the U.S drugmaker’s new COVID-19 vaccine. EQT said it was bidding 220 crowns per Recipharm share, a 22.9% premium to Recipharm’s closing price on Friday. “Recipharm has generated strong gro...

EQT Offers to Buy Recipharm of Sweden in $2.1 Billion Deal Bloomberg 12/14/2020 Charles Daly © Bloomberg Recipharm shares rose as much as 23% to 220.20 kronor, near the bid price, in Stockholm Monday morning. (Bloomberg) -- Private equity firm EQT AB agreed to buy Swedish pharmaceuticals company Recipharm AB for $2.1 billion, marking the latest in a wave of drug industry acquisitions. EQT said Monday it’s offering shareholders 220 kronor in cash per share, 23% more than Friday’s closing price. Recipharm is a 25-year-old company that specializes in outsourcing contract...